These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 15778099)

  • 1. Interferon beta, progressive MS, and brain atrophy.
    Chaudhuri A
    Lancet Neurol; 2005 Apr; 4(4):208-9. PubMed ID: 15778099
    [No Abstract]   [Full Text] [Related]  

  • 2. Does interferon beta help in secondary progressive MS?
    Cohen JA; Antel JP
    Neurology; 2004 Nov; 63(10):1768-9. PubMed ID: 15557486
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progressive course of multiple sclerosis].
    Zavalishin IA; Zakharova MN; Peresedova AV; Askarova LSh; Stoĭda NI; Krotenkova MV; Oleĭnikov VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():26-31. PubMed ID: 12418389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI and assessment of treatment in multiple sclerosis.
    Miller DH; Thompson AJ; Kappos L
    Brain; 2001 May; 124(Pt 5):1052-3. PubMed ID: 11335707
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
    Molyneux PD; Kappos L; Polman C; Pozzilli C; Barkhof F; Filippi M; Yousry T; Hahn D; Wagner K; Ghazi M; Beckmann K; Dahlke F; Losseff N; Barker GJ; Thompson AJ; Miller DH
    Brain; 2000 Nov; 123 ( Pt 11)():2256-63. PubMed ID: 11050025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A meta-analysis of interferon-beta in the secondary progressive multiple sclerosis].
    Fan X; Yang L
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(21):1484-9. PubMed ID: 19953902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landmark papers in multiple sclerosis.
    Cross AH
    Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
    [No Abstract]   [Full Text] [Related]  

  • 8. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis].
    Lebrun C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C; Montalban X; Tintoré M; Nos C; Río J; Aymerich FX; Brieva L; Téllez N; Perkal H; Comabella M; Galán I; Calle D; Sastre-Garriga J; Rovira A
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.
    Montalban X
    Mult Scler; 2004 Jun; 10 Suppl 1():S62; discussion 62-4. PubMed ID: 15218812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
    Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
    Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Nadeau SE
    Neurology; 2006 May; 66(9):1457-8; author reply 1457-8. PubMed ID: 16682694
    [No Abstract]   [Full Text] [Related]  

  • 17. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 20. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
    Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
    Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.